Evidence map›Paper›PMID 28971906›Full record

ArticleHaematologica2017

Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of

Ibrahim Aldoss, Anh Pham, Sierra Min Li, Ketevan Gendzekhadze, Michelle Afkhami, Milhan Telatar, Hao Hong, Abbas Padeganeh, Victoria Bedell, Thai Cao and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Transplant options and outcomes for TP53 myeloid disease.Hematology. American Society of Hematology. Education Program · 2024
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. International journal of molecular sciences · 2020
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Ibrahim AldossDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Anh PhamDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Sierra Min LiDepartment of Information Sciences, Division of Biostatistics, City of Hope, Duarte, CA, USA.
Ketevan GendzekhadzeHLA Laboratory, City of Hope, Duarte, CA, USA.
Michelle AfkhamiDepartment of Pathology, City of Hope, Duarte, CA, USA.
Milhan TelatarDepartment of Pathology, City of Hope, Duarte, CA, USA.
Hao HongDepartment of Pathology, City of Hope, Duarte, CA, USA.
Abbas PadeganehDepartment of Cytogenetics, City of Hope, Duarte, CA, USA.
Victoria BedellDepartment of Cytogenetics, City of Hope, Duarte, CA, USA.
Thai CaoDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Samer K KhaledDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Monzr M Al MalkiDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Amandeep SalhotraDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Haris AliDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Ahmed AribiDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Joycelynne PalmerDepartment of Information Sciences, Division of Biostatistics, City of Hope, Duarte, CA, USA.
Patricia AounDepartment of Pathology, City of Hope, Duarte, CA, USA.
Ricardo SpielbergerDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Anthony S SteinDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
David SnyderDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Margaret R O'DonnellDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Joyce Murata-CollinsDepartment of Cytogenetics, City of Hope, Duarte, CA, USA.
David SenitzerHLA Laboratory, City of Hope, Duarte, CA, USA.
Dennis WeisenburgerDepartment of Pathology, City of Hope, Duarte, CA, USA.
Stephen J FormanDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Vinod PullarkatDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Guido MarcucciDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Raju PillaiDepartment of Pathology, City of Hope, Duarte, CA, USA.
Ryotaro NakamuraDepartment of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA rnakamura@coh.org.

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

Therapy-related myelodysplastic syndrome is a long-term complication of cancer treatment in patients receiving cytotoxic therapy, characterized by high-risk genetics and poor outcomes. Allogeneic hematopoietic cell transplantation is the only potential cure for this disease, but the prognostic impact of pre-transplant genetics and clinical features has not yet been fully characterized. We report here the genetic and clinical characteristics and outcomes of a relatively large cohort of patients with therapy-related myelodysplastic syndrome (n=67) who underwent allogeneic transplantation, comparing these patients to similarly treated patients with

Indexed as

FemaleHumansMaleMiddle AgedMutationMyelodysplastic SyndromesStem Cell TransplantationTransplantation, HomologousTumor Suppressor Protein p53TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID28971906
PMCPMC5709102

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.